05/12 | Japan Index Ends in Red; Toyota Clocks Record-High FY22 Attributable Income but Project.. | MT |
05/11 | Takeda Pharmaceutical's FY22 Attributable Profit Falls 39% | MT |
05/11 | GLOBAL MARKETS LIVE : Coinbase, Roblox, Apple, EA, Hasbro... | |
05/11 | TRANSCRIPT : Takeda Pharmaceutical Company Limited, Q4 2022 Earnings Call, May 11, 2022 | CI |
05/11 | TRANSCRIPT : Takeda Pharmaceutical Company Limited, 2022 Earnings Call, May 11, 2022 | CI |
05/11 | Takeda Pharmaceutical Posts Higher Profit, Revenue in Fiscal 2021 | MT |
05/11 | Takeda Pharmaceutical Posted Fourth-Quarter Net Loss | DJ |
05/11 | Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in FY2022 | BU |
05/11 | Takeda Pharmaceutical Company Limited Provides Consolidated Earnings Guidance for the F.. | CI |
05/11 | Takeda Pharmaceutical Company Limited Declares Dividend for the Year Ended March 31, 20.. | CI |
05/11 | Takeda Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended .. | CI |
04/29 | OncoSec Medical Names Robert Arch CEO; Shares Rise Early | MT |
04/29 | HilleVax Shares Gain Ground in Trading Debut After Upsized IPO | DJ |
04/28 | CENTOGENE and Takeda Extend Market Access and Expansion Partnership to Advance Patient .. | AQ |
04/27 | Takeda Recognized as 2022 ISPE Facility of the Year Awards Winner in Two Categories | AQ |
04/26 | Takeda Holds Fourth Quarter and Full-Year FY2021 Earnings Call on May 11 | AQ |
04/26 | Takeda Recognized as the 2022 ISPE Facility of the Year Awards Winner in Two Categories | BU |
04/25 | TAKEDA PHARMACEUTICAL : Holds Fourth Quarter and Full-Year FY2021 Earnings Call on May 1 | PU |
04/25 | HilleVax Sets IPO at 10.3 Million Shares; Sees Pricing at $16-$18 | DJ |
04/22 | Takeda Pharmaceutical Says Livtencity Treatment Reduces Hospitalizations in Transplant .. | MT |
04/22 | Takeda Presents New Exploratory Analysis Showing Patients Treated With LIVTENCITY&trade.. | BU |
04/20 | Takeda to Manufacture Novavax's COVID-19 Vaccine Following Government Approval and Purc.. | MT |
04/19 | Novavax Shares Fall 1% Following Nuvaxovid Approval in Japan | DJ |
04/19 | Takeda's TAKHZYRO (lanadelumab-flyo) Prefilled Syringe Now Available for People With He.. | AQ |
04/19 | Finch Therapeutics to Cut 20% of Staff in Restructuring | DJ |
04/19 | CORRECTION : Takeda Pharmaceutical's COVID-19 Vaccine Nuvaxovid Gets Approval in Japan | MT |
04/19 | Takeda Pharmaceutical's COVID-19 Vaccine Nuvaxoid Gets Approval in Japan | MT |
04/18 | Takeda Announces Approval of Nuvaxovid® COVID-19 Vaccine for Primary and Booster Immuni.. | BU |
04/18 | Takeda Announces Approval of Nuvaxovid Covid-19 Vaccine for Primary and Booster Immuniz.. | CI |
04/18 | Takeda Pharmaceutical's Prefilled Takhzyro Syringe Now Available in US | MT |
04/18 | Takeda's TAKHZYRO® (lanadelumab-flyo) Prefilled Syringe Now Available for People With H.. | BU |
04/18 | Takedas TAKHZYRO® (lanadelumab-flyo) Prefilled Syringe Now Available for People W.. | CI |
04/14 | Takeda Pharmaceutical Closes $797 Million Share Buyback | MT |
04/13 | Takeda Announces Completion of Acquisition of Own Shares | BU |
04/13 | Tranche Update on Takeda Pharmaceutical Company Limited's Equity Buyback Plan announced.. | CI |
04/12 | Takeda Says Phase 3 Trial of Takhzyro in Pediatric Hereditary Angioedema Meets Safety, .. | MT |
04/12 | Takeda's TAKHZYRO® (lanadelumab) Open Label Phase 3 Study Met Its Objectives in Childre.. | BU |
04/12 | Takedas Takhzyro® (Lanadelumab) Open Label Phase 3 Study Met Its Objectives in Ch.. | CI |
04/12 | TAKEDA : Pediatric Hereditary Angioedema Study Meets Objectives | DJ |
04/12 | Takeda Pharmaceutical Company Limited 's Equity Buyback announced on October 28, 2021, .. | CI |
04/09 | Exclusive Speaker Interview with Ester Lovsin Barle Ahead of the 6th Annual Highly Pote.. | AQ |
04/06 | Evozyne Partners With Takeda Pharmaceutical to Develop Gene Therapies | MT |
04/05 | Takeda and the New York Academy of Sciences Announce 2022 Innovators in Science Award W.. | BU |
04/04 | Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting | AQ |
04/01 | Takeda Pharmaceutical Company Limited Announces Executive Changes | CI |
04/01 | Australian Shares Post Small Loss Amid Decline in Business Confidence | MT |
04/01 | Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting | BU |
04/01 | Tranche Update on Takeda Pharmaceutical Company Limited's Equity Buyback Plan announced.. | CI |
04/01 | Takeda Pharmaceutical Company Limited acquired A-Digital, Inc. | CI |
03/31 | Hasten Biopharmaceutic Co., Ltd. completed the acquisition of A Portfolio of Five Selec.. | CI |
03/30 | Japan Index Comes under Pressure; JCR Pharmaceuticals and Takeda Sign Licensing and All.. | MT |
03/30 | TAKEDA PHARMACEUTICAL COMPANY LIMITE : Ex-dividend day for final dividend | FA |
03/29 | Takeda's TAKHZYRO (lanadelumab) Approved in Japan for Prophylaxis Against Acute Attacks.. | AQ |
03/29 | JCR Pharmaceuticals and Takeda Sign Licensing and Alliance Deal for Gene Therapies Deve.. | MT |
03/28 | Takeda Pharma Secures Approval for Takhzyro to Prevent Hereditary Angioedema in Japan | MT |
03/28 | Takeda's TAKHZYRO® (lanadelumab) Approved in Japan for Prophylaxis Against Acute Attack.. | BU |
03/28 | Takeda Receives Approval from the Ministry of Health, Labour and Welfare for TAKHZYRO | CI |
03/28 | U.S. FDA approves UCB's drug for rare childhood epilepsy | RE |
03/23 | COVID vaccine maker Moderna flags Japan ambition with sumo sponsorship | RE |
03/22 | What you need to know about the coronavirus right now | RE |
03/22 | Former Takeda vaccine chief to lead new COVID antiviral venture Aerium | RE |
03/22 | Takeda Provides Natpara U.S. Regulatory Update | CI |
03/10 | Japan considers offering fourth COVID vaccine shot - Yomiuri | RE |
03/09 | Denali Therapeutics Initiates Phase 1/2 Clinical Trial of DNL593 to Treat Frontotempora.. | MT |
03/08 | TRANSCRIPT : Takeda Pharmaceutical Company Limited Presents at 42nd Annual Cowen Health Ca.. | CI |
03/07 | COVID SCIENCE-Omicron infections contagious for at least 6 days; Takeda drug shows prom.. | RE |
03/01 | Takeda - Interim Phase 4 Data Support TAKHZYRO (lanadelumab) as an Effective Treatment .. | AQ |
02/28 | Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduc.. | BU |
02/28 | Takeda Announces Interim Phase 4 Data Support Takhzyro® (Lanadelumab) as an Effective T.. | CI |
02/22 | Code Biotherapeutics, Inc. Announces Collaboration with Takeda to Use Proprietary 3Dna .. | CI |
02/21 | Takeda - Alofisel(darvadstrocel) Shows Clinical Remission Rate at Six-Months in the Rea.. | AQ |
02/18 | Alofisel®▼ (darvadstrocel) Shows Clinical Remission Rate at Six-Months in the Rea.. | BU |
02/18 | Takeda Announces the First Six-Month Interim Analysis Results from Inspire | CI |
02/16 | Ipsen - Cabometyx in combination with Opdivo demonstrated continued survival and qualit.. | AQ |
02/14 | Takeda Pharmaceutical Clocks Decline in Fiscal Q3 Attributable Profit | MT |